Evaluation of Risk Factors for Carbapenem-Resistant Klebsiella Pneumoniae Bacteremia

Kıran P., Gençer S., Batırel A.

Southern Clinics of Istanbul Eurasia, vol.31, no.1, pp.54-58, 2020 (Peer-Reviewed Journal)


NTRODUCTION: In recent years, carbapenem-resistant Klebsiella pneumoniae infections have become an important health problem in our country and all over the world. In this study, we aimed to identify the risk factors of carbapenem-resistant K. pneumoniae bacteremia.
METHODS: Patients who suffered from Klebsiella pneumoniae bacteremia between December 2016 and May 2018 were included prospectively in this study. Patients were divided into groups according to carbapenem resistance and risk factors were analyzed under variable and multivariable logistic regression model.
RESULTS: Of the fifty-three patients were included in this study, 27 patients infected with carbapenem-resistant K. pneumoniae and 26 patients infected with carbapenem-suspectible K. pneumoniae. Risk factors for carbapenem-resistant K. pneumoniae bacteremia according to univariate analysis were listed prior hospitalization (p=0.043; OR=3.20; 95% CI: 1.04–9.85), admission to intensive care unit (p=0.001; OR=10.91; 955 CI: 2.61–45.6), use of beta-lactams/beta-lactamase inhibitor combination (p<0.001; OR=41.67; 95% CI: 7.57–229.2) and use of glycopeptides (p=0.001; OR=7.92; 95% CI: 2.31–27.1). Before hospitalization (p=0.016; OR=9.64; 95% CI: 1.54–60.46) and use of beta-lactams/beta-lactamase, inhibitor combination (p<0.001; OR=38.45; 95% CI: 6.04–244.85) were identified as independent risk factors for carbapenem resistance in multivariate analysis.
DISCUSSION AND CONCLUSION: According to our study, before hospitalization, the use of beta-lactams/beta-lactamase inhibitor combination was the major risk factor for carbapenem-resistant Klebsiella pneumoniae bacteremia.